Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Cuminaldehyde [122-03-2]

Cuminaldehyde [122-03-2]

Stampa Stampa
Entra

Cat# HY-Y0790-5g

Size : 5g

Marca : MedChemExpress


Description

Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL), α-glucosidase (IC50=0.5 mg/mL) and lipoxygenase (IC50=1370 μM). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases[1][2][3][4][5][6][7].

IC50 & Target

α-synuclein Aggregation

 

In Vitro

Cuminaldehyde (1 mM; 24-96 h) can effectively inhibit α-synuclein (α-SN) fibrillation. The presence of α-SN fibrillation inducer Spermidine (HY-B1776) enhances the inhibitory effect, which is even stronger than the inhibitory effect of Baicalein (HY-N0196)[1].
Cuminaldehyde (0-160 μM; 12-48 h) inhibits the proliferation of human colon COLO 205 cells and induces cell apoptosis[2].
Cuminaldehyde (0.5 and 1.5 μM; 5 d) inhibits the growth of Aspergillus flavus (IC50=0.25 μL/mL) and induces necrosis of Aspergillus flavus[5].
Cuminaldehyde (0-0.8 μL/mL; 5 d) inhibits the synthesis of aflatoxin (AFB1), a secondary metabolite of Aspergillus flavus[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cuminaldehyde Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Human colon COLO 205 cells
Concentration: 0, 10, 20, 40, 80 and 160 μM
Incubation Time: 12-48 h
Result: Reduced mitochondrial membrane potential, leads to lysosomal vacuolization, upregulates acidic compartment volume and cytotoxicity.

Real Time qPCR[5]

Cell Line: Aspergillus flavus
Concentration: 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 and 0.8 μL/mL
Incubation Time: 5 days
Result: Reduced the expression of genes related to AFB1 synthesis.
In Vivo

Cuminaldehyde (5-20 mg/kg; intratumoral injection; once a day for 42 days) inhibits tumor growth in mice bearing human colorectal cancer COLO 205 xenografts[2].
Cuminaldehyde (50-200 mg/kg; i.g.; single dose injection 30 minutes before hot plate test) significantly reduces the latency of nociceptive response in rats in hot plate test[6].
Cuminaldehyde (12.5-50 mg/kg; i.p.; single dose injection 30 minutes before the test) significantly inhibits pain perception in mice with abdominal pain induced by Acetic acid (HY-Y0319) and formalin[6].
Cuminaldehyde (25-100 mg/kg; i.p.; once daily for 14 days) significantly alleviates allodynia and hyperalgesia in rats with chronic constriction injury (CCI) model[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Human colorectal cancer COLO 205 xenograft mice[2]
Dosage: 5, 10 and 20 mg/kg
Administration: Intratumoral injection
Result: Inhibited tumor growth in mice, with tumor volumes reduced by 48.9% and 69.4% at doses of 10 and 20 mg/kg, respectively.
Animal Model: Chronic constriction injury (CCI) model rat[6]
Dosage: 25, 50 and 100 mg/kg
Administration: i.p.; 1 time per day for 14 days
Result: Reduced serum TNF-α and IL-1β levels.
Masse moléculaire

148.21

Formule

C10H12O
CAS No.
Appearance

Liquid (Density: 0.977 g/cm3)

Color

Colorless to light yellow

SMILES

O=CC1=CC=C(C(C)C)C=C1
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (674.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.7474 mL 33.7371 mL 67.4741 mL
5 mM 1.3495 mL 6.7474 mL 13.4948 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références